Axol Bioscience Ltd, a provider of iPSC-derived cells, media, and characterization services, and Censo Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies, have signed a merger agreement. The new entity will become a provider of product and services in the iPSC-based neuroscience, immune cell, and cardiac modeling for drug discovery and screening markets. Axol’s investors include Jonathan Milner and EIS fund manager, Calculus Capital. Censo’s major investor is leading Edinburgh-based EIS fund manager, Par Equity.
Under the terms of the agreement, Axol CEO, Liam Taylor, and the Axol senior leadership team will take over the management of the combined entity, with the intent to migrate the brand to Axol Bioscience. The agreement sees Censo’s interim CEO, Tom Stratford, appointed non-executive director of the combined board, on behalf of Par Equity.
Taylor said, “Axol has experienced a rapid increase in demand for their iPSC-based products and services over the last three years. Merging with CENSO immediately and significantly grows our scientific team and breadth of expertise. That, and the addition of two sites for iPSC-derived cell line manufacturing and custom service work, will increase our production capacity and future-proof our organization to ensure demand can continue to be met with the short lead times and quality that our customers depend on.”
Stratford added, “Censo’s strength is our scientific team, as trusted partners in designing, executing, and managing custom project work. The combined entity will now be able to leverage Axol’s strength in iPSC-derived cells as well as complementary services such as electrophysiology to further our ability and efficiency to serve customers. We bring to bear capabilities, bandwidth, and expertise to scale the manufacturing of those tools in a way that benefits both customer bases and the wider market.”